15.27
-0.63 (-3.96%)
| Penutupan Terdahulu | 15.90 |
| Buka | 15.98 |
| Jumlah Dagangan | 245,245 |
| Purata Dagangan (3B) | 306,005 |
| Modal Pasaran | 574,474,688 |
| Harga / Jualan (P/S) | 11.15 |
| Harga / Buku (P/B) | 2.43 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2026 |
| EPS Cair (TTM) | -2.49 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.25% |
| Nisbah Semasa (MRQ) | 21.47 |
| Aliran Tunai Operasi (OCF TTM) | -39.28 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.34 M |
| Pulangan Atas Aset (ROA TTM) | -22.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Contineum Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.17 |
|
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.82% |
| % Dimiliki oleh Institusi | 79.99% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |